What is more likely is that the FDA will eventually allow the trial to continue, but request tighter eligibility criteria for patients being evaluated for treatment, thereby slightly reducing the size of the addressable market for one or all of Iovance's therapies. Investors probably won't be pleased with that outcome, as it would imply a downward revision of the company's projected earnings from sales of any therapies it commercializes. However, if regulators give the thumbs up to the melanoma program, it might not matter, as the stock will soar.